Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Validus Pharmaceuticals LLC ("Validus"), together with Wood Creek Capital Management, LLC ("Wood Creek"), announced today the acquisition of the U.S. rights to several well-known product lines from Sanofi US: Anzemet® (dolasetron mesylate) Injection and Tablets, Claforan® (cefotaxime) Injection/IM/IV, Demerol® (meperidine hydrochloride) Tablets, Drisdol® (ergocalciferol) Capsules and Oral Solution, Hiprex® (methenamine hippurate) Tablets, Lasix® (furosemide) Tablets, Norpramin® (desipramine hydrochloride) Tablets and Trental ® (pentoxifylline) Tablets.

Wood Creek acquired the Sanofi US products on December 10, 2015 through a new company, US Pharmaceuticals Holdings II LLC. Validus will serve as the exclusive manager for the ex-Sanofi US lines. These products present Validus with opportunities to generate sales in several new therapeutic markets and represents a significant growth catalyst for the company.

"The management and marketing of these significant new product lines fulfills another major step in Validus Pharmaceuticals' strategic plan for continued growth," commented James Hunter, Validus CEO. "Adding these lines of medications immediately enables Validus to serve additional large and growing markets and continues to expand our presence in the U.S. pharmaceutical market."

"The acquisition of U.S. rights to these Sanofi US products continues to demonstrate our belief in, and commitment to, the mature branded pharmaceuticals market," said Matthew Sandoval, Wood Creek Managing Director. "This is another in a series of transactions completed with large pharmaceutical companies by Wood Creek. We are excited about the potential for our strategy."

As manufacturing and distribution of these products transitions to Validus, the company is working rapidly in order to assure both physicians and patients of a continued product supply under their label. Validus will be communicating directly with distributors and prescribing physicians regarding the availability of all these products.


Validus Pharmaceuticals LLC


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study investigates patients' perspectives on use of race-based algorithms in clinical decision-making